Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Cancer
    October 2025
  1. ISLAMI F, Wiese D, Schafer EJ, Sung H, et al
    Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021.
    Cancer. 2025;131:e70073.
    >> Share

  2. NIERENGARTEN MB
    Therapies for patients with previously treated lung cancer: Two second-line therapies receive accelerated approval for treatment.
    Cancer. 2025;131:e70076.
    >> Share

    September 2025
  3. FATHI JT, Cinciripini PM, DePrimo MJ, Houston TP, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening.
    Cancer. 2025;131:e35972.
    >> Share

  4. COOPER AJ, Garbo E, Arfe A, Conroy M, et al
    Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
    Cancer. 2025;131:e70081.
    >> Share

  5. FLOREZ N, Patel S, Wakelee HA, Rotow J, et al
    Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.
    Cancer. 2025;131:e70060.
    >> Share

  6. VOLK RJ, Lettieri JS, Leal VB, Duhon GF, et al
    The quality of patient decision aids for lung cancer screening: Results from an environmental scan.
    Cancer. 2025;131:e70008.
    >> Share

  7. HUANG L, Zeng F, Huang P, Ren D, et al
    Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.
    Cancer. 2025;131:e70063.
    >> Share

    August 2025
  8. OLSON JMG, Knight JR, Copeland AM, Ohlander KA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Addressing planning for lung cancer interventions at the state and local level through the creation of the National Lung Cancer Roundtable Planning Tool.
    Cancer. 2025;131:e35954.
    >> Share

  9. STUDTS JL, Carter-Bawa L, Hamann HA, Smith RA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Changing the lung cancer story: Addressing survivorship, stigma, and nihilism to facilitate transformation.
    Cancer. 2025;131:e35969.
    >> Share

  10. HOWLADER N, Cronin KA, Yu M, Miller D, et al
    Urban-rural disparities in lung cancer incidence and mortality patterns in Black and White populations.
    Cancer. 2025;131:e70004.
    >> Share

  11. NIERENGARTEN MB
    Effective and efficient large-scale lung cancer screening: Low-dose computed tomography screening for lung cancer enables early diagnosis in asymptomatic, high-risk individuals and has been shown to reduce lung cancer-related mortality.
    Cancer. 2025;131:e35956.
    >> Share

    July 2025
  12. BROWN LM, Wilkins SG, Bansal VV, Su DG, et al
    Consensus guideline for the management of peritoneal mesothelioma.
    Cancer. 2025;131:e35868.
    >> Share

    June 2025
  13. LEAL TA, Wang Y, Dowlati A, Chay CH, et al
    Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
    Cancer. 2025;131:e35938.
    >> Share

  14. PASSIGLIA F, Pepe F, Russo G, Garbo E, et al
    Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer.
    Cancer. 2025;131:e35917.
    >> Share

    May 2025
  15. DENNEHY C, Conroy MR, Forde PM
    Immunotherapy for resectable lung cancer.
    Cancer. 2025;131:e35849.
    >> Share

  16. KILICKAP S, Ozguroglu M, Sezer A, Gumus M, et al
    Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 >/=50.
    Cancer. 2025;131:e35864.
    >> Share

  17. HOFF CO, Feng L, Bonini F, Sousa LG, et al
    Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.
    Cancer. 2025;131:e35901.
    >> Share

  18. SHOU J, Chen J, Guo Q, Hong W, et al
    Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial.
    Cancer. 2025;131:e35822.
    >> Share

  19. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    >> Share

  20. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
    Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
    Cancer. 2025;131:e35862.
    >> Share

  21. THOMAS QD, Vendrell JA, Khellaf L, Cavaillon S, et al
    Artificial intelligence-driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer.
    Cancer. 2025;131:e35882.
    >> Share

    April 2025
  22. MACHIDA N, Okumura T, Boku N, Kishimoto J, et al
    A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G).
    Cancer. 2025;131:e35807.
    >> Share

    March 2025
  23. SHIELDS MD, Chiang AC, Byers LA
    Top advances of the year: Small cell lung cancer.
    Cancer. 2025;131:e35770.
    >> Share

  24. BOGDANSKA W, Paik PK
    From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping.
    Cancer. 2025;131 Suppl 1:e35782.
    >> Share

  25. JIMENEZ MUNARRIZ BE, Khan S, Li Y, Ghazali N, et al
    Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment.
    Cancer. 2025;131 Suppl 1:e35786.
    >> Share

  26. SHAVERDASHVILI K, Burns TF
    Advances in the treatment of KRAS(G12C) mutant non-small cell lung cancer.
    Cancer. 2025;131 Suppl 1:e35783.
    >> Share

  27. PARISI C, Planchard D
    BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice.
    Cancer. 2025;131 Suppl 1:e35781.
    >> Share

  28. HOE HJ, Solomon BJ
    Treatment of non-small cell lung cancer with RET rearrangements.
    Cancer. 2025;131 Suppl 1:e35779.
    >> Share

  29. KIM J, Park S, Ku BM, Ahn MJ, et al
    Updates on the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer.
    Cancer. 2025;131 Suppl 1:e35778.
    >> Share

  30. REINHORN D, Moskovitz M, Tap WD, Li BT, et al
    Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies.
    Cancer. 2025;131 Suppl 1:e35780.
    >> Share

  31. DESILETS A, Repetto M, Yang SR, Drilon A, et al
    Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions.
    Cancer. 2025;131 Suppl 1:e35784.
    >> Share

    February 2025
  32. SANDS JM, Champiat S, Hummel HD, Paulson KG, et al
    Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
    Cancer. 2025;131:e35738.
    >> Share

    January 2025
  33. NIERENGARTEN MB
    First person profile: Julie Brahmer, MD: Dr Brahmer's research paved the way for the first immunotherapy agent to receive US Food and Drug Administration approval for the treatment of lung cancer.
    Cancer. 2025;131:e35686.
    >> Share

  34. PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al
    Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.
    Cancer. 2025;131:e35664.
    >> Share

  35. GANTI AK, Fruth B, Rimner A, Waqar S, et al
    Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance.
    Cancer. 2025;131:e35663.
    >> Share

  36. MCCOLL KS, Ajay A, Wang H, Wildey GM, et al
    Identification of HEPACAM2 as a novel and specific marker of small cell carcinoma.
    Cancer. 2025;131:e35557.
    >> Share

    December 2024
  37. POTTER AL, Kuhan S, Senthil P, Mansur A, et al
    The 2021 US Preventive Services Task Force lung cancer screening eligibility criteria disproportionately exclude younger Black patients with lung cancer.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35676.
    >> Share

  38. ZHANG D, Rohatgi A
    Improving survival for patients with metastatic non-small cell lung cancer in the immunotherapy era.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35675.
    >> Share

    November 2024
  39. DESAI P, Zhou Y, Grenet J, Handelman SK, et al
    Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.
    Cancer. 2024;130:3879-3887.
    >> Share

    October 2024
  40. NIERENGARTEN MB
    Durvalumab not cost-effective with current pricing strategies for stage III NSCLC: The drug remains inaccessible to many patients for whom it is indicated as a standard of care after chemoradiation.
    Cancer. 2024;130:3236.
    >> Share

    September 2024
  41. FOX AH, Osarogiagbon RU, Farjah F, Jett JR, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non-small cell lung cancer.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34628.
    >> Share

  42. FARJAH F, Barta JA, Wood DE, Rivera MP, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline-concordant lung cancer staging.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34627.
    >> Share

  43. ROY-CHOWDHURI S, Mani H, Fox AH, Tsao A, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34926.
    >> Share

  44. BARTA JA, Farjah F, Thomson CC, Dyer DS, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Optimizing strategies for lung nodule evaluation and management.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.35181.
    >> Share

  45. BACKHUS LM, Chang CF, Sakoda LC, Chambers SR, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Lung cancer in women.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.35083.
    >> Share

  46. FATHI JT, Barry AM, Greenburg GM, Henschke CI, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high-quality lung cancer screening.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.34621.
    >> Share

  47. LEWIS JA, Klein DE, Eberth JM, Carter-Bawa L, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Provider engagement and outreach.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.34555.
    >> Share

  48. VOLK RJ, Myers RE, Arenberg D, Caverly TJ, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Current challenges and future directions for shared decision making for lung cancer screening.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.35382.
    >> Share

  49. KAZEROONI EA, Wood DE, Rosenthal LS, Smith RA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Introduction.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.35385.
    >> Share

  50. NIERENGARTEN MB
    ASCO 2024: Advances in lung cancer treatments and care: A new standard of care therapy based on the results of the LAURA study underscores the need for testing for epidermal growth factor receptor (EGFR) mutations in patients with unresectable stage I
    Cancer. 2024;130:2894.
    >> Share

    August 2024
  51. NIERENGARTEN MB
    First person profile: Heather A. Wakelee, MD: For more than 20 years, she has served in multiple functions, including developing research programs in lung cancer and thymoma that include clinical trials and population science approaches.
    Cancer. 2024;130:2730.
    >> Share

  52. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    >> Share

    July 2024
  53. WANG Y, Kondrat K, Adhikari J, Nguyen Q, et al
    Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database-based study.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35476.
    >> Share

    June 2024
  54. CHO H, Kwon H, Kim SH, Ahn HM, et al
    Seasonal influences on the efficacy of anti-programmed cell death (ligand) 1 inhibitors in lung cancer.
    Cancer. 2024 Jun 28. doi: 10.1002/cncr.35454.
    >> Share

  55. MAKAREM M, Janne PA
    Top advances of the year: Targeted therapy for lung cancer.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35423.
    >> Share

  56. YABROFF KR, Mittu K, Halpern MT
    Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.
    Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380.
    >> Share

  57. EDWARDS DM, Pirzadeh M, Van T, Jiang R, et al
    Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer.
    Cancer. 2024 Jun 10. doi: 10.1002/cncr.35340.
    >> Share

  58. BYUN JY, Aiyeolemi A, Qdaisat A, Park C, et al
    Association between epidermal growth factor receptor-tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non-small cell lung cancer.
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35424.
    >> Share

    May 2024
  59. AREDO JV, Wakelee HA
    Top advances of the year: Perioperative therapy for lung cancer.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35357.
    >> Share

  60. LEAL TA, Ramalingam SS
    Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35353.
    >> Share

  61. YOUNG LK, Halmos B
    Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?
    Cancer. 2024 May 6. doi: 10.1002/cncr.35350.
    >> Share

    April 2024
  62. AJABNOOR AM, Parisi R, Zghebi SS, Ashcroft DM, et al
    Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019.
    Cancer. 2024;130:1316-1329.
    >> Share

    March 2024
  63. VITA E, Monaca F, Milardi D, Mastrantoni L, et al
    Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
    Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293.
    >> Share

  64. WISNIVESKY JP, Mudd J, Stone K, Slatore CG, et al
    Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Cancer. 2024 Mar 21. doi: 10.1002/cncr.35286.
    >> Share

  65. CITTOLIN-SANTOS GF, Knapp B, Ganesh B, Gao F, et al
    The changing landscape of small cell lung cancer.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35281.
    >> Share

  66. NIERENGARTEN MB
    Updated American Cancer Society lung cancer screening guidelines: The new guidelines offer expanded criteria recommended for lung cancer screening based on age, smoking status, and smoking history.
    Cancer. 2024;130:656-657.
    >> Share

  67. WEST HJ, Pennell NA
    Lessons from ADAURA: Can we improve on a positive trial?
    Cancer. 2024;130:659-664.
    >> Share

    February 2024
  68. TAN AC, Lai GGY, Saw SPL, Chua KLM, et al
    Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263.
    >> Share

  69. MORGENSZTERN D
    The expanding role of circulating tumor DNA in resectable non-small cell lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268.
    >> Share


  70. Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study".
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165.
    >> Share

  71. NIERENGARTEN MB
    Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC.
    Cancer. 2024;130:495-496.
    >> Share

  72. DESAI A, Smith CJ, Pritchett JC, Leventakos K, et al
    Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC).
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35250.
    >> Share

  73. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    >> Share

  74. RUSSELL AM, Pack AP, Bailey SC, Weldon CB, et al
    A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35240.
    >> Share

    January 2024
  75. IOCOLANO M, Yegya-Raman N, Friedes C, Wang X, et al
    Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
    Cancer. 2024 Jan 31. doi: 10.1002/cncr.35230.
    >> Share

  76. FLOREZ N, Kaufman RA, Yanez-Sarmiento A, Abioye O, et al
    When the unimaginable happens: Lung cancer diagnosis during pregnancy.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35227.
    >> Share

  77. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    >> Share

  78. KRATZER TB, Bandi P, Freedman ND, Smith RA, et al
    Lung cancer statistics, 2023.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35128.
    >> Share

  79. ROLFO C, Del Re M, Russo A
    Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers.
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35203.
    >> Share

  80. HONG J, Lee J, Park S, Jung HA, et al
    Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Cancer. 2024 Jan 2. doi: 10.1002/cncr.35175.
    >> Share

  81. MEZA R, Cao P, de Nijs K, Jeon J, et al
    Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling study.
    Cancer. 2024;130:244-255.
    >> Share

    December 2023
  82. TRAN TN, Lee S, Kim HJ, Lee Y, et al
    Treatment-related cardiovascular events in patients with non-small cell lung cancer: Evidence from real-world data with a competing risks approach.
    Cancer. 2023 Dec 16. doi: 10.1002/cncr.35143.
    >> Share

  83. WANG S, Xie T, Li Y, Guo L, et al
    Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
    Cancer. 2023;129:3873-3883.
    >> Share

  84. ZHAO X, Yang M, Fan J, Wang M, et al
    Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
    Cancer. 2023 Dec 6. doi: 10.1002/cncr.35130.
    >> Share


  85. Immunotherapy plus stereotactic radiation therapy improves event-free survival in early-stage non-small cell lung cancer.
    Cancer. 2023;129:3680.
    >> Share

    November 2023
  86. GUAN MC, Ding Q, Ning J, Zhu H, et al
    Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus.
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35111.
    >> Share

  87. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus".
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35134.
    >> Share

  88. GRIESINGER F, Ramagopalan S, Cheung WY, Wilke T, et al
    Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.
    Cancer. 2023 Nov 7. doi: 10.1002/cncr.35094.
    >> Share

  89. LANDY R, Cheung LC, Young CD, Chaturvedi AK, et al
    Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34758.
    >> Share

  90. HENDRICK RE, Smith RA
    Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34855.
    >> Share

    October 2023
  91. VAN VEGGEL BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, et al
    A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    Cancer. 2023 Oct 31. doi: 10.1002/cncr.35090.
    >> Share

  92. MAHAR AL, Biggs K, Hansford RL, Derksen S, et al
    Stage IV breast, colorectal, and lung cancer at diagnosis in adults living with intellectual or developmental disabilities: A population-based cross-sectional study.
    Cancer. 2023 Oct 30. doi: 10.1002/cncr.35068.
    >> Share

  93. CHOI E, Luo SJ, Ding VY, Wu JT, et al
    Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35069.
    >> Share

  94. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    >> Share

  95. FLOREZ N, Kiel L, Meza K, Wei Z, et al
    Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057.
    >> Share

  96. VAN TUIJL LA, Basten M, Pan KY, Vermeulen R, et al
    Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis.
    Cancer. 2023;129:3287-3299.
    >> Share


  97. Erratum to "JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer".
    Cancer. 2023 Oct 13. doi: 10.1002/cncr.35064.
    >> Share

  98. TAMMEMAGI MC, Cina K, Kitts AKB, Koop D, et al
    Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Cancer. 2023 Oct 9. doi: 10.1002/cncr.34947.
    >> Share

    September 2023
  99. LU S, Guo X, Li Y, Liu H, et al
    Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
    Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003.
    >> Share

  100. TAMMEMAGI MC
    Time to quit using quit time as a lung cancer screening eligibility criterion.
    Cancer. 2023 Sep 1. doi: 10.1002/cncr.34999.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016